Benefits and Risks of ETI Therapy in Cystic Fibrosis Patients with Liver Transplants
发布者：Unknown
·发布于: 2025-12-13
A discussion regarding the potential clinical benefits and associated risks of using elexacaftor-tezacaftor-ivacaftor (ETI) therapy specifically for cystic fibrosis patients who have previously undergone liver transplantation.